MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q2
hinzugefügt 08.08.2023
Eagle Pharmaceuticals Operativer Cashflow 2011-2025 | EGRX
Operativer Cashflow Jährlich Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.7 M | 28.2 M | 49.5 M | 56 M | 52.4 M | 58.9 M | 53.2 M | -9.72 M | -13.8 M | -5.88 M | -15.5 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 58.9 M | -15.5 M | 27.6 M |
Operativer Cashflow Vierteljährlich Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -33.5 M | - | 13.1 M | 26.4 M | -16.6 M | - | 20.1 M | 19.1 M | 10.5 M | - | 29.7 M | 24.1 M | 3.16 M | - | 59.2 M | 48.6 M | 26.2 M | - | 14.3 M | 10.6 M | 4.92 M | - | 33 M | 25.1 M | -12.4 M | - | 13.7 M | 484 K | 3.11 M | - | 7.08 M | 13.7 M | 25.8 M | -7.88 M | -13.9 M | -6.74 M | -2.07 M | 23 K | -5.56 M | -2.83 M | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 59.2 M | -33.5 M | 10.3 M |
Operativer Cashflow anderer Aktien in der Arzneimittelhersteller
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
49.6 M | $ 0.73 | -3.6 % | $ 51.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 1.7 | -2.59 % | $ 183 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-12.7 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-211 M | $ 5.11 | -5.46 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
-206 M | $ 12.37 | 8.32 % | $ 633 M | USA |
 |
Evoke Pharma
EVOK
|
-4.98 M | $ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | $ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
-18 M | $ 7.18 | 1.99 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
3.84 M | $ 46.29 | -1.64 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
-466 K | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
1.03 B | $ 6.9 | -0.36 % | $ 2.52 B | Canada |
 |
Organogenesis Holdings
ORGO
|
14.2 M | $ 4.78 | -0.83 % | $ 629 M | USA |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
Pacira BioSciences
PCRX
|
189 M | $ 26.61 | 1.22 % | $ 1.23 B | USA |
 |
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.8 | -6.19 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 3.11 | 22.92 % | $ 43.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-51.4 M | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
-9.41 M | $ 0.88 | -5.3 % | $ 20.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 3.55 | -1.11 % | $ 4.41 M | USA |
 |
Solid Biosciences
SLDB
|
-100 M | $ 5.75 | -2.04 % | $ 235 M | USA |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-51.7 M | $ 4.34 | 6.91 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
363 M | $ 12.77 | -2.78 % | $ 1.75 B | USA |
 |
ProPhase Labs
PRPH
|
28.6 M | $ 0.11 | -0.35 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.99 | -9.95 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
-21.7 M | $ 2.4 | -0.83 % | $ 324 M | USA |
 |
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
-353 K | $ 1.19 | -0.83 % | $ 5.13 M | USA |
 |
SCYNEXIS
SCYX
|
60.2 M | $ 0.64 | -0.91 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
7.91 M | $ 11.01 | -9.4 % | $ 6.8 B | Canada |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
-16 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
3 B | $ 11.68 | 0.29 % | $ 14.2 B | USA |